Acute Immunotherapy in Neuroimmunology

Autoimmune neurologic disorders encompass a broad range of conditions affecting the central and peripheral nervous systems, unified by the principle that early immunotherapy initiation is critical for optimal outcomes. Acute immunotherapy aims to halt ongoing immune-mediated injury, reverse neurologic deficits where possible, and bridge patients to long-term maintenance strategies. The choice and urgency of treatment depend on the underlying antibody mechanism, clinical severity, and the specific neuroimmunologic diagnosis. Treatment should not be delayed while awaiting antibody results when clinical suspicion is high — empiric immunotherapy is appropriate and often necessary to prevent irreversible neurologic damage.

General Principles

The approach to acute immunotherapy in neuroimmunologic disorders is guided by several fundamental principles. Autoimmune neurologic disorders require rapid recognition and treatment initiation, as delays in therapy are consistently associated with poorer outcomes across virtually all conditions. The pathogenic mechanism of the underlying autoantibody fundamentally determines treatment responsiveness and prognosis.

Empiric immunotherapy is appropriate when the clinical presentation is consistent with an autoimmune neurologic disorder, even before serologic confirmation. Antibody testing may take days to weeks to return, and delaying treatment during this period can result in irreversible neurologic injury. The clinical syndrome, CSF findings, and MRI features should guide the decision to initiate treatment.

IV Corticosteroids

Intravenous corticosteroids are the most widely used first-line acute immunotherapy across neuroimmunologic conditions. Their broad anti-inflammatory properties make them effective against multiple immune pathways simultaneously, providing rapid onset of action in the acute setting.

Mechanism of Action

Corticosteroids exert their anti-inflammatory effects through multiple mechanisms: reduction of blood-brain barrier permeability, decreased leukocyte migration into the CNS, suppression of pro-inflammatory cytokine production (including IL-1, IL-6, and TNF-alpha), inhibition of T-cell activation and proliferation, and induction of lymphocyte apoptosis. This broad mechanism of action makes them effective as initial empiric therapy even when the specific immune mechanism is uncertain.

Dosing Protocols

Indications Across Neuroimmunologic Conditions

IV methylprednisolone is a cornerstone of acute treatment for:

• MS relapses: Shortens relapse duration, though does not affect long-term outcome
• NMOSD acute attacks: First-line treatment, often combined with PLEX for severe attacks
• MOGAD acute attacks: First-line, but requires prolonged oral taper due to steroid recrudescence
• Autoimmune encephalitis: Part of first-line combination therapy (with IVIg and/or PLEX)
• Neurosarcoidosis: Mainstay of acute treatment, followed by prolonged oral maintenance
• Neurorheumatologic CNS manifestations: Including neuropsychiatric SLE and CNS vasculitis

MOGAD-Specific Consideration: Steroid Recrudescence

In MOGAD, a particularly important phenomenon is steroid recrudescence — the recurrence or worsening of neurologic symptoms during the oral prednisone taper. This occurs more frequently in MOGAD than in MS or NMOSD and requires a slower, more prolonged taper (minimum 4–6 weeks, often longer). Some patients require re-escalation to higher steroid doses before attempting a more gradual taper.

Adverse Effects

• Insomnia and sleep disturbance (very common during pulse dosing)
• Steroid-induced psychosis or mood changes
• Hypertension
• Hyperglycemia (monitor in diabetic patients)
• Gastric irritation (consider proton pump inhibitor prophylaxis)
• With prolonged oral taper: weight gain, osteoporosis, adrenal suppression, cushingoid features, increased infection risk

Intravenous Immunoglobulin (IVIg)

Intravenous immunoglobulin is a pooled human immunoglobulin product with complex, multifactorial immunomodulatory properties. It is a first-line treatment for many neuroimmunologic conditions and is particularly valuable when PLEX is not available, is contraindicated, or when the clinical setting favors a less invasive approach (e.g., pediatric patients).

Mechanism of Action

IVIg modulates the immune system through multiple pathways: Fc receptor modulation on immune effector cells, anti-idiotypic antibody neutralization of pathogenic autoantibodies, complement cascade interference (scavenging activated complement components), and modulation of B-cell and T-cell function. This multifactorial mechanism makes it broadly effective across different autoimmune pathways.

Dosing

Indications

• NMOSD acute attacks: Used when PLEX is unavailable or as adjunctive therapy
• Autoimmune encephalitis: Part of first-line combination therapy
• Pediatric demyelinating attacks: Often preferred over PLEX due to less invasive access
• MOGAD: Effective in acute attacks; also used as maintenance therapy for relapse prevention
• Neuromuscular autoimmune disorders: Myasthenia gravis crisis, Guillain-Barré syndrome

Adverse Effects

Plasma Exchange (PLEX / Plasmapheresis)

Plasma exchange is the most direct method of removing pathogenic circulating factors, including autoantibodies, immune complexes, and activated complement components. It is considered the most effective acute treatment for severe autoimmune neurologic attacks, particularly those mediated by cell-surface antibodies where direct removal of pathogenic antibodies produces rapid clinical improvement.

Mechanism of Action

PLEX physically removes circulating pathogenic antibodies, immune complexes, complement factors, and cytokines from the patient's plasma. The removed plasma is replaced with albumin or fresh frozen plasma. This direct removal mechanism makes PLEX particularly effective for cell-surface antibody disorders where the pathogenic antibody is directly accessible in the circulation.

Standard Protocol

Indications

• NMOSD acute attacks: Often considered the most effective acute treatment; early initiation (day 3–4 after IVMP) improves outcomes
• Severe autoimmune encephalitis: Particularly effective in cell-surface antibody-mediated encephalitis
• Steroid-refractory demyelinating attacks: MS relapses or MOGAD attacks not responding to IVMP
• Catastrophic antiphospholipid syndrome: Rapid removal of antiphospholipid antibodies
• Neuromuscular emergencies: Myasthenic crisis, Guillain-Barré syndrome

Adverse Effects

• Hypotension: Due to volume shifts during the exchange procedure
• Hypocalcemia: Caused by citrate anticoagulant binding calcium; manifests as perioral tingling, paresthesias, muscle cramps
• Coagulopathy: Removal of clotting factors; monitor fibrinogen and coagulation parameters
• Central line complications: Infection, thrombosis, pneumothorax (if central venous access required)
• Allergic reactions: To replacement fluids (albumin or fresh frozen plasma)

PLEX is generally considered superior to IVIg in the acute setting for severe attacks, particularly in NMOSD and severe autoimmune encephalitis. However, it requires specialized equipment, trained personnel, and often central venous access, which may limit its availability in some settings.

Second-Line Acute Immunotherapy

When first-line therapies (corticosteroids, IVIg, PLEX) fail to produce adequate clinical improvement, second-line agents should be initiated without delay. In some conditions, particularly NMDA-R encephalitis, there is growing evidence that early second-line therapy significantly improves outcomes.

Rituximab (Anti-CD20)

Rituximab is an anti-CD20 monoclonal antibody that causes rapid and sustained B-cell depletion. Originally developed for B-cell lymphomas, it has become one of the most widely used immunotherapies in neuroimmunology. Many centers now use rituximab as early or even first-line therapy in severe autoimmune encephalitis.

Key evidence in NMDA-R encephalitis: Early rituximab administration (within 4 weeks of symptom onset) is associated with 89% of patients achieving mRS <2 (good functional outcome), compared with only 57% when rituximab is delayed beyond 4 weeks. Many pediatric centers now use rituximab as first-line therapy in NMDA-R encephalitis given this compelling outcome data.

Rituximab Adverse Effects

• Infusion reactions: Fever, chills, rigors, urticaria; managed with premedication (acetaminophen, diphenhydramine, methylprednisolone) and slowing infusion rate
• Increased infection risk: Particularly upper respiratory and urinary tract infections
• Hypogammaglobulinemia: Cumulative risk with repeated cycles; monitor IgG levels and supplement if recurrent infections occur
• Progressive multifocal leukoencephalopathy (PML): Very rare but serious; JC virus reactivation
• Late-onset neutropenia: Typically occurs 1–5 months after infusion; usually self-limited
• Hepatitis B reactivation: Screen all patients before initiation; prophylactic antivirals for HBsAg+ or anti-HBc+ patients

Cyclophosphamide

Cyclophosphamide is an alkylating agent with broad immunosuppressive properties. It is particularly useful in conditions where T-cell mediated damage is prominent (intracellular antibody/paraneoplastic disorders) and in severe, refractory autoimmune neurologic conditions.

Primary indications:

• Severe or refractory autoimmune encephalitis (both cell-surface and intracellular antibody types)
• Paraneoplastic disorders — may target pathogenic T cells more effectively than B-cell depleting agents
• Neuropsychiatric SLE
• Severe CNS vasculitis
• Refractory neurosarcoidosis

Adverse effects: Nausea and vomiting (premedicate with antiemetics), myelosuppression (nadir at 10–14 days), hemorrhagic cystitis, alopecia, increased infection risk, long-term malignancy risk (bladder cancer, hematologic malignancies), and infertility (discuss fertility preservation before initiating in reproductive-age patients).

Tocilizumab (Anti-IL-6 Receptor)

Tocilizumab is an anti-IL-6 receptor monoclonal antibody with an emerging role as second-line or rescue therapy in several neuroimmunologic conditions:

• Fulminant MOGAD: Recently used for cases not responsive to corticosteroids and PLEX; may provide rapid clinical benefit through IL-6 pathway blockade
• NMOSD maintenance: Proven superior to azathioprine in preventing relapses
• Refractory autoimmune encephalitis: Used as rescue therapy when first-line and rituximab fail
• Dosing: 8 mg/kg IV every 4 weeks (maintenance); IV formulation for acute use

Disease-Specific Acute Treatment Approaches

The choice and intensity of acute immunotherapy varies significantly across neuroimmunologic conditions. The following table summarizes the recommended approach for each major condition.

The Role of Tumor Removal

In paraneoplastic disorders and certain autoimmune encephalitides, tumor identification and treatment may be the single most effective intervention. The immune response is driven by cross-reactivity between tumor antigens and neuronal antigens, and removing the antigenic stimulus can be critical for halting disease progression.

NMDA-R Encephalitis and Ovarian Teratoma

Approximately 30–50% of NMDA-R encephalitis cases in young women are associated with ovarian teratoma. Early teratoma removal significantly improves outcomes:

• Teratoma resection reduces relapse risk from approximately 35% to 10–15%
• Surgery should be performed as early as possible once identified
• If no teratoma found on initial imaging, surveillance imaging is recommended given the possibility of occult or developing tumors
• Immunotherapy should proceed concurrently with surgical planning — do not delay immunotherapy while awaiting surgery

Paraneoplastic Disorders

For intracellular antibody-associated paraneoplastic syndromes (anti-Hu, anti-Yo, anti-CV2), cancer treatment through surgery, chemotherapy, or radiation may be the most effective intervention. Immunotherapy alone often has limited benefit in these conditions because the neuronal damage is primarily mediated by cytotoxic T cells and tends to be irreversible. However, combination of cancer treatment with immunotherapy may provide additional benefit in some cases.

Opsoclonus-Myoclonus Syndrome

In pediatric opsoclonus-myoclonus syndrome, neuroblastoma resection is a critical component of management. However, neurologic symptoms may persist or relapse even after complete tumor removal, and ongoing immunotherapy (corticosteroids, IVIg, rituximab) is often necessary.

Monitoring and Treatment Response

Assessment of treatment response in acute neuroimmunologic conditions requires careful clinical monitoring, often with serial neurologic examinations, repeat neuroimaging, and sometimes serial antibody titers (particularly for cell-surface antibodies where titers may correlate with disease activity). Key principles include:

• Clinical response timeline: Improvement may occur within days (PLEX, corticosteroids) to weeks (rituximab, cyclophosphamide); allow adequate time before declaring treatment failure
• Escalation threshold: If no meaningful clinical improvement after first-line therapy, escalate to second-line agents promptly — delays in escalation are associated with worse outcomes, particularly in autoimmune encephalitis
• Antibody titers: In cell-surface antibody disorders, declining titers generally correlate with clinical improvement, though clinical response should drive treatment decisions rather than titers alone
• Transition to maintenance: Once acute stabilization is achieved, transition to appropriate long-term maintenance immunotherapy to prevent relapse (particularly important in NMOSD, where maintenance should begin at diagnosis)

References

1. McKeon A, Pittock SJ. Overview and diagnostic approach in autoimmune neurology. Continuum (Minneap Minn). 2024;30(4):960-994.
2. Irani SR. Autoimmune encephalitis. Continuum (Minneap Minn). 2024;30(4):995-1020.
3. Sechi E, Flanagan EP. Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease. Continuum (Minneap Minn). 2024;30(4):1052-1090.
4. McCombe JA. Neurologic manifestations of rheumatologic disorders. Continuum (Minneap Minn). 2024;30(4):1189-1225.